Блокада ɑ1-адренорецепторов: роль в терапии психических расстройств

Полный текст:


Аннотация

Цель: представить обзор нарушений функции ɑ1-адренорецепторов (А1АР) при различных психических расстройствах с целью выявить наиболее перспективные направления клинических и экспериментальных исследований.

Результаты: среди препаратов, связывающихся с А1АР наибольшее значение для клинического изучения приобрели их антагонисты. Основной фокус исследований вовлеченности А1АР направлен на изучение нейрокогнитивных расстройств, расстройств, связанных со стрессом и шизофрении. При данных расстройствах была продемонстрирована целесообразность и перспективность клинического изучения проникающих через гематоэнцефалический барьер (ГЭБ) антагонистов А1АР.

Вывод: активное изучение А1АР и норадренергической функции определяет механизмы ее нарушений и перспективы терапевтического вмешательства.


Об авторе

T. С. Сюняков
ООО «Пфайзер»
Россия

Сюняков Тимур Сергеевич - кандидат медицинских наук.

Москва.



Список литературы

1. Kozisek М.Е., Bylund D.B. Norepinephrine/epinephrine. In: Hoboken N.J. Handbook of contemporary neuropharmacology. USA: John Wiley & Sons; Inc., 2007. doi: 10.1002/9780470101001.hcn006.

2. Arnsten A.F.T., Raskind M.A. Taylor F.B., Connor D.F. The effects of stress exposure on prefrontal cortex: Translating basic research into successful treatments for post-traumatic stress disorder. Neurobiology of Stress. 2015;l(l):89-99. doi: 10.1016/j.ynstr.2014.10.002.

3. Yang L.J., Liu X., Liu D.X., Jiang H., Mao X.Q., Wang C., Pan F. Effects of different adrenergic blockades on the stress resistance of Wistarrats. Neurosd. Lett. 2012;511(2):95-100. doi: 10.1016/j.neulet2012.01.046.

4. Arnsten A.F.T. Stress weakens prefrontal networks: molecular insults to higher cognition. Nat. Neurosci. 2015; 18(10): 1376-1385. doi: 10.1038/nn.4087.

5. Haj-Dahmane S., Shen R.-Y. Chronic stress impairs 1-adrenoceptor-induced endocannabinoid-dependent synaptic plasticity in the dorsal raphe nucleus. J. Neurosci. 2014;34(44): 14560-14570. doi: 10.1523/JNEUROSCI.1310-14.2014.

6. Drazinic C. et al. Neurotransmitters and Receptors in Psychiatric Disorders. In: The American Psychiatric Association Publishing Textbook of Psychopharmacology. American Psychiatric Association Publishing, 2017. Ed. Alan F. Schatzberg Charles B. Nemeroff. doi: 10.1176/appi.books.97816153n624.as02.

7. Knauber J., Muller W.E. Subchronic treatment with prazosin improves passive avoidance learning in aged mice: possible relationships to alpha-l-receptor up-regulation. J. Neural Transm. 2000;107(12):1413-1426. doi: 10.1007/s007020070005.

8. Lee T.W., Cotecchia S., Milligan G. Upregulation of the levels of expression and function of a constitutively active mutant of the hamster alphalB-adrenoceptor by ligands that act as inverse agonists. Biochem. J. 1997;325(Pt 3): 733-739. doi: 10.1042/bj3250733

9. Stevens P.A., Bevan N., Rees S., Milligan G. Resolution of inverse agonist-induced upregulation from constitutive activity of mutants of the alpha(lb)-adrenoceptor. Mol. Pharmacol. 2000;58(2):438-448. doi: https://doi. org/10.1124/mol.58.2.438

10. Gannon M., Che P., Chen Y., Jiao K., Roberson E.D., Wang Q. Noradrenergic dysfunction in Alzheimer's disease. Front. Neurosci. 2015;9(JUN):1-12. doi: 10.3389/fnins.2015.00220.

11. Purkayastha S., Raven P. The functional role of the alpha-1 adrenergic receptors in cerebral blood flow regulation. Indian J. Pharmacol. 2011;43(5):502. doi: 10.4103/0253-7613.84950.

12. Piascik M.T., Perez D.M. Alphal-adrenergic receptors: new insights and directions. J. Pharmacol. Exp. Ther. 2001; 298(2):403-410.

13. Fitzgerald P.J. Noradrenaline transmission reducing drugs may protect against a broad range of diseases. Auton. Autacoid Pharmacol 2015;34(3-4):15-26. doi: 10.1111/aap.12019.

14. Chen Z., Minneman K.P., Minneman P K.P. Recent progress in al-adrenergic receptor research Acta Pharmacol. Sin. 2005;26(11): 1281-1287. doi: 10.1111/j.l745-7254.2005.00224.x.

15. Black C.E. et al. Effect of nicotine on vasoconstrictor and vasodilator responses in human skin vasculature. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2001;281(4): R1097- 1104. doi: 10.1152/ajpregu.2001.281.4.R1097.

16. Hock C.E., Passmore J.C. Mechanisms mediating canine renal vasoconstriction induced by nicotine infusion. Life Sci. 1985;37(21): 1997-2003. doi: 10.1016/0024-3205(85)90030-X.

17. Lecerof H. et al. Acute effects of doxazosin and atenolol on smoking-induced peripheral vasoconstriction in hypertensive habitual smokers. J. Hypertens. Suppl. 1990;8(5):29- 33.

18. Cryer P.E., Haymond M.W., Santiago J.V., Shah S.D. Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events. N. Engl. J. Med. 1976;295(ll):573 - 577. doi: 10.1056/NEJM197609092951101.

19. Haase N., Herse F., Spallek B., Haase H., Morano L., Qadri F., Szijarto L.A., Rohm I., Yilmaz A., Warrington J.P., Ryan M.J., Gollasch M., Muller D.N., Dechend R., Wallukat G. Amyloid-3 peptides activate al-adrenergic cardiovascular receptors Hypertens. (Dallas, Tex. 1979). 2013;62(5):966 - 972. doi: 10.1161/HYPERTENSIONAHA.113.01348.

20. Dietrich H.H., Xiang C., Han B.H., Zipfel G.J., Holtzman D.M. Soluble amyloid-beta, effect on cerebral arteriolar regulation and vascular cells. Mol. Neurodegener. 2010;5:15. doi: 10.1186/1750-1326-5-15

21. Smith E.E., Greenberg S.M. Beta-amyloid blood vessels, and brain function. Stroke. 2009;40(7):2601-2606. doi: 10.1161/STROKEAHA.108.536839.

22. Russo-Neustadt A., Cotman C.W. Adrenergic receptors in Alzheimer's disease brain: selective increases in thecerebella of aggressive patients. J. Neurosci. 1997;17(14):5573-5580. doi: https://doi.org/10.1523/JNEUROSCI.17-14-05573.1997.

23. Antonsdottir I.M., Smith J., Kettz M., Porsteinsson A.P. Advancements in the treatment of agitation in Alzheimer's disease. Expert Opin. Pharmacother. 2015;16(11):1649-1656. doi: 10.1517/14656566.2015.1059422.

24. Peskind E.R. et al. Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: a placebo-controlled study Alzhei¬mer Dis. Assoc. Disord. 19(l):23-28. doi: 10.1097/01.wad.0000155067.16313.5e.

25. Wang LY., Shofer J.B., Rohde K., Hart K.L., Hoff D.J., Mc- Fall Y.H., Raskind M.A., Peskind E.R. Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggressioa Am. J. Geriatr. Psychiatry. 2009;17(9):744-751. doi: 10.1097/JGP.0b013e3181ab8c61.

26. Fioravanti M., Ricker L Nicergoline for dementia and other age associated forms of cognitive impairment In: Cochrane Database of Systematic Reviews / Ed. M. Fioravanti. Chichester, UK: John Wiley & Sons, Ltd 2001. № 4. P. CD003159. doi: 10.1002/14651858.CD003159.

27. Winblad B., Fioravanti M., Dolezal T., Logina I., Milanov I.G., Popescu D.C., Solomon A. Therapeutic use of nicergoline. Clin. Drug Investig. 2008;28(9):533-552. doi: 10.2165/00044011-200828090-00001.

28. Zajdel P., Bednarski M., Sapa J., Nowak G. Ergotamine and nicergoline — facts and myths. Pharmacol. Reports. Institute of Pharmacology, Polish Academy of Sciences. 2015;67(2):360-363. doi: 10.1016/j.pharep2014.10.010.

29. Fioravanti М„ Nakashima Т., Xu J., Garg A. A systematic review and meta-analysis assessing adverse event profile and tolerability of nicergoline BMJ Open. 2014;4(7):e005090. doi: 10.1136/bmjopen-2014-005090.

30. Пономарева E.B., Телешова E.C., Сюняков T.C. Сочетание нейродегенеративных и сосудистых механизмов в патогенезе деменций позднего возраста. Психиатрия. 2017;76(4): 97-107.

31. Пономарева Е.В. Применение ницерголина в геронтологической практике. Психиатрия. 2016;71(3): 106—120.

32. Bes A. et al. A 24-month double-blind placebo-controlled multicentre pilot study of the efficacy and safety of nicergoline 60 mg per day in elderly hypertensive patients with leukoaraiosis. Eur. J. NeuroL 1999;6(3):313-322. doi: 10.1046/j.l468-1331.1999.630313.x.

33. Boulu P. Effets du Sermion® surles troubles mn. esiques et les fonctions dela vie de relation. Tempo Med. 1990,397:24- 27.

34. Carfagna N., Cavanus S., Damiani D., Salmoiraghi P., Fariello R., Post C. Modulation of phosphoinositide turnover by chronic nicergoline in rat brain. Neurosd. Lett. 1996; 209:189-192. doi: 10.1016/0304-3940(96)12634-3.

35. Karczewski P. et al. Agonistic autoantibodies to the ɑ1-adrenergic receptor and the β2-adrenergic receptor in Alzheimer's and vascular dementia. Scand. J. ImmunoL 2012;75(5):524-530. doi: 10.1111/j.l365-3083.2012.02684.x.

36. Zhou Z., Liao Y., Li L., Wei F., Wang B., Wei Y.f Wang M., Cheng X. Vascular damages in rats immunized by ɑ1-Adrenoceptor peptides. Cell. Mol. ImmunoL 2008;5(5):349-356. doi: 10.1038/cmi.2008.43.

37. Karczewski P. et al. Antibodies to the al-adrenergic receptor cause vascular impairments in rat brain as demonstrated by magnetic resonance angiography. PLoS One/ed. Herholz K. 2012;7(7):e41602. doi: 10.1371/journal.pone.0041602.

38. Wenzel K. et al. Potential relevance of al-adrenergic receptor autoantibodies in refractory hypertension. PLoS One. 2008;3(ll):e3742. doi: 10.1371/joumal.pone.0003742.

39. Kung S., Espinel L, Lapid M.I. Treatment of nightmares with prazosin: A systematic review. Mayo Clinic Proceedings. 2012;87(9):890-900. doi: 10.1016/j.mayocpL2012.05.015.

40. Akinsanya A., Marwaha R., Tampi R.R. Prazosin in children and adolescents with posttraumatic stress disorder who have nightmares. J. Clin. Psychopharmacol. 2017;37(1):84- 88. doi: 10.1097/JCP.0000000000000638.

41. Baisley S.K., Fallace K.L, Rajbhandari A.K., Bakshi V.P. Mutual independence of 5-HT(2) and al-noradrenergic receptors in mediating deficits in sensorimotor gating. Psychopharmacology (Berl). 2012;220(3):465-479. doi: 10.1007/s00213-011-2490-2.

42. Bakshi V.P., Geyer M.A. Phencyclidine-induced deficits in prepulse inhibition of startle are blocked by prazosin, an alpha-1 noradrenergic antagonist J. Pharmacol. Exp. Ther. 1997;283(2):666-674.

43. Alsene K.M. et aL Disruption of prepulse inhibition after stimulation of central but not peripheral alpha-1 adrenergic receptors. Neuropsychopharmacology. 2006;31(10):2150- 2161. doi: 10.1038/sj.nppi1300989.

44. Nikiforuk A. Quetiapine ameliorates stress-induced cogni¬tive inflexibility in rats. Neuropharmacology. 2013;64:357- 364. doi: 10.1016/j.neuropharm.2012.06.042.

45. Romon Т., Planas А.М., Adell A. Blockade of МК-801-induced heat shock protein 72/73 in rat brain by antipsychotic and monoaminergic agents targeting 02, 5-HT1A, 5-HT2A and al-adrenergic receptors. CNS Neurol. Disord. Drug Targets. 2014; 13(1): 104-111. doi: 10.2174/18715273113129990110.

46. Minzenberg M.J., Yoon J.H. An index of relative central a-adrenergic receptor antagonism by antipsychotic medications. Exp. Clin. Psychopharmacol. 20H;19(l):31-39. doi: 10.1037/a0022258.

47. Stahl S.M. Stahfs essential psychopharmacology: neuroscientific basis and practical applications. Cambridge university press 2013.


Дополнительные файлы

Для цитирования: Сюняков T.С. Блокада ɑ1-адренорецепторов: роль в терапии психических расстройств. Психиатрия. 2018;(78):150-157.

For citation: Syunyakov T.S. Blockade of Alpha-1-adrenoceptors: role in the therapy of mental disorders. Psychiatry. 2018;(78):150-157. (In Russ.)

Просмотров: 50

Обратные ссылки

  • Обратные ссылки не определены.


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1683-8319 (Print)